Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

Clinical trial NCT05935748 · TERMINATED

Trial details

NCT number: NCT05935748
Sponsor: NiKang Therapeutics, Inc.
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

ccRCC Clear Cell Renal Cell Carcinoma Kidney Cancer Kidney Neoplasms Renal Cancer Renal Neoplasms Recurrent Renal Cell Carcinoma Metastatic Renal Cell Carcinoma Refractory Renal Cell Carcinoma Advanced Renal Cell Carcinoma Carcinoma Neoplasms

Start date: 2023-07-28
Primary completion: 2025-06-30
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.